

Merus

Merus to Participate in Upcoming Investor Conferences

February 1, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- [Merus N.V.](#) (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclronics[®] and Triclronics[®]), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences:

- Guggenheim Healthcare Talks/Oncology Conference: Wednesday, February 8 at 11:20-11:45 a.m. ET
- SVB Securities Global Biopharma Conference: Wednesday, February 15 at 10:00-10:30 a.m. ET
- Citi's 2023 Oncology Leadership Summit: Thursday, February 23 at 10:00-11:00 a.m. ET

The webcasts of the presentations will be contemporaneously available on the [investors page](#) of the Company's website. Archived presentations will also be available there for a limited time after the event.

About Merus

[Merus](#) is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as [Multiclronics[®]](#). Multiclronics[®] are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit [Merus' website](#), and [Twitter](#).

Multiclronics[®], Biclronics[®] and Triclronics[®] are registered trademarks of Merus N.V.

Investor and Media Inquiries:

Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl

Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
k.farren@merus.nl

Merus